| Symbol | GMAB |
|---|
| Name | GENMAB A/S |
|---|
| Sector | HEALTH CARE |
|---|
| Region | Europe |
|---|
| Industry | - |
|---|
| Address | 10179 United States NY 383 Madison Avenue Floor 11 |
|---|
| Telephone | 1-800- 990-1135 |
|---|
| Fax | — |
|---|
| Email | — |
|---|
| Website | http://www.genmab.com |
|---|
| Incorporation | DK |
|---|
| Incorporated On | 1999 |
|---|
| Employees | — |
|---|
| Fiscal Year | 12/31 |
|---|
| Public Since | — |
|---|
| Exchanges | OTC;NASDAQ |
|---|
| Auditor | — |
|---|
| Audit Status | AUDITED |
|---|
| Reporting Status | U.S. Reporting: SEC Reporting |
|---|
| CIK | 0001434265 |
|---|
| Description | Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.
Additional info from NASDAQ:
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmabs proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmabs leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered wth Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.
Additional info from OTC:
Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. |
|---|
2026-05-12 17:46
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Read more
2026-05-08 19:05
Major Shareholder Announcement
Read more
2026-05-07 15:02
Genmab Announces Financial Results for the First Quarter of 2026
Read more
2026-04-17 16:20
GENMAB A/S (GMAB) Files Form 6-K
Read more
2026-04-17 15:24
GENMAB A/S (GMAB) Files Form 6-K
Read more
2026-04-17 14:56
Genmab A/S Share Capital Reduction
Read more
2026-04-14 16:01
GENMAB A/S (GMAB) Files Form 6-K
Read more
2026-04-14 14:44
Major Shareholder Announcement
Read more
2026-04-14 12:26
GENMAB A/S (GMAB) Files Form 6-K
Read more
2026-04-14 10:23
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
Read more
No clinical trials found for this company.
No clinical products found for this company.